NCT06940219 Delayed Against Rapid Sequence Induction in Adults With Medical Diseases Undergoing Emergency Endotracheal Intubation.
| NCT ID | NCT06940219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Leipzig University Medical Center |
| Condition | Intubation in Intensive Care Units |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2025-06-27 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2025-06-27 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if it is feaseble to conduct a superiority trial comparing two methods for endotracheal intubation in critically ill patients. It will also learn about validity of outcomes regarding endotracheal intubation. The main questions it aims to answer are: * Does performing intubation via Delayed Sequence Induction lower the incidence of severe hemodynamic complications compared to Rapid Sequence Induction? * How are hemodynamic complications in the severely ill to be measured in order to minimize bias? Participants will: * receive emergency endotracheal intubation via Delayed or Rapid Sequence induction * receive a phone call 90 days after endotracheal intubation * outcome parameters outside of follow up phone calls will be routinely collected during the regular ICU-stay, there won't be any additional testing
Eligibility Criteria
Inclusion Criteria: * Adult patients 18 years or older in need of emergency endotracheal intubation in the following 60 minutes. * The planned operateur routinely performs endotracheal intubation in critically ill patients. Exclusion Criteria: * Endotracheal Intubation performed during cardiopulmonary resuscitation or during "unstable ROSC", defined as Norepinephrine or Epinephrine dose \> 0,5 µg/kgKG/min after return of spontaneous circulation. * Participation in the study is not warranted because of increased risk for the patient or otherwise not justifiable (e.g. active oral bleeding). * Known allergy against Ketamine, Esketamine, Midazolam or Rocuronium. * Known contraindication against Ketamine, Esketamine Midazolam or Rocuronium. * Known or anticipated difficult airway with indication for awake fiberoptic intubation. * Women with known pregnancy or breastfeeding.
Contact & Investigator
Anton J Pelka
PRINCIPAL INVESTIGATOR
Interdisciplinary Medical ICU, Leipzig Medical University Center
Frequently Asked Questions
Who can join the NCT06940219 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Intubation in Intensive Care Units. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06940219 currently recruiting?
Yes, NCT06940219 is actively recruiting participants. Contact the research team at anton.pelka@medizin.uni-leipzig.de for enrollment information.
Where is the NCT06940219 trial being conducted?
This trial is being conducted at Leipzig, Germany.
Who is sponsoring the NCT06940219 clinical trial?
NCT06940219 is sponsored by Leipzig University Medical Center. The principal investigator is Anton J Pelka at Interdisciplinary Medical ICU, Leipzig Medical University Center. The trial plans to enroll 200 participants.